TrialDiabetes, obesity & metabolism2022

A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.

Soree Ryang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.